AMY-101 / Novel C3 inhibitors

About Amyndas Pharmaceuticals

Amyndas Pharmaceuticals is a clinical-stage biotech focused on developing novel complement inhibitors, with a core technology rooted in the compstatin family of C3-targeting peptides. Its lead asset, AMY-101, has completed Phase 2a trials in periodontal disease and has been investigated in severe COVID-19, demonstrating proof-of-concept for C3 inhibition. The company is advancing programs in significant unmet needs, including Age-Related Macular Degeneration (AMD) and other complement-mediated disorders, positioning itself in a high-value but competitive therapeutic area.

Therapeutic Areas